Sumiar Prostate-specific antigen (PSA) was recently found in 30% of female breast tumours. In this study we have examined if PSA circulates in the blood of breast cancer patients and if serum PSA has any clinical application. We have compared serum PSA levels between women with and without breast cancer, between women with PSA-positive and PSA-negative breast cancer and between women with breast cancer before and after surgical removal of the tumour. We found that for women (Oesterling, 1991 : Armbruster, 1993 . PSA production is regulated by androgenic steroids, which bind to androgen receptors and up-regulate transcription of the PSA gene (Young et al., 1991). PSA was until recently thought to be produced only by prostatic epithelial cells and is currently used as a biochemical marker for diagnosis and monitoring of prostate adenocarcinoma. We have reported that PSA concentrations > 0.03 ng per mg of total protein could be detected in 30% of cytosolic extracts from female breast tumours . The PSA immunoreactive species in female breast cancer has molecular weight identical to PSA from seminal plasma (Diamandis et al., 1994) . PSA mRNA was identified by polymerase chain reaction in PSA protein-positive breast tumours but not in PSA proteinnegative breast tumours (Monne et al., 1994) . The PSA cDNA from breast tumours was identical in sequence to PSA cDNA from prostatic tissue (Monne et al., 1994 The rest included ductal in situ (2%), medullary (2%), papillary (4.5%), tubular (6.5%), inflammatory (3.5%), tubulolobular (4%), muciparous (2.5%) and others (2.5%).
Prostate-specific antigen (PSA) is a 33 kDa serine protease found at high concentrations in seminal plasma and prostate epithelial cells and at relatively low concentrations in male serum (Oesterling, 1991 : Armbruster, 1993 . PSA production is regulated by androgenic steroids, which bind to androgen receptors and up-regulate transcription of the PSA gene (Young et al., 1991) . PSA was until recently thought to be produced only by prostatic epithelial cells and is currently used as a biochemical marker for diagnosis and monitoring of prostate adenocarcinoma. We have reported that PSA concentrations > 0.03 ng per mg of total protein could be detected in 30% of cytosolic extracts from female breast tumours . The PSA immunoreactive species in female breast cancer has molecular weight identical to PSA from seminal plasma (Diamandis et al., 1994) . PSA mRNA was identified by polymerase chain reaction in PSA protein-positive breast tumours but not in PSA proteinnegative breast tumours (Monne et al., 1994) . The PSA cDNA from breast tumours was identical in sequence to PSA cDNA from prostatic tissue (Monne et al., 1994) . Preliminary clinical studies have shown that PSA in breast cancer is associated with the presence of the progesterone receptor and that patients with PSA-positive tumours have a lower risk of relapse and death in comparison with patients whose tumours are PSA negative . Thus, PSA is a new candidate favourable prognostic indicator in female breast cancer.
A number of previous studies have shown that PSA is undetectable in the serum of most women Rock et al., 1987; Vihko et al., 1990) and that fewer than 5% of women have serum PSA concentrations > 0.05 iLg 1- Kyoto, Japan) . using a mobile phase of 0.1 mol 1-' sodium sulphate and 0.1 mol 1-l sodium dihydrogen phosphate, pH 6.80. The column used was a Bio-Sil SEC-250. 600 mm x 75 mm (BioRad Labs. Richmond. CA. USA) and was calibrated with a molecular weight standard solution from BioRad. The flow rate was 0.5 ml min-'. After injection of 50-300 jul of each sample. fractions of 0.5 ml were collected and analysed for PSA using the method outlined below.
MVeasurement of PSA and total protein PSA concentration in serum and in tumour cytosol was measured in duplicate with a time-resolved immunofluorometric PSA assay (Yu and Diamandis. 1993) . which has a biological detection limit of 0.01 jg 1-'. PSA concentration in tumour cytosols was expressed as ng of PSA per mg of total protein. The total protein concentration (mg ml-') in the cytosols was measured in duplicate using a commercial kit based on the bicinchoninic acid method (Pierce. Rockford, IL. USA).
Statistical analysis PSA concentrations in serum were categorised into three groups as follows: PSA <0.010ig 1-'. PSA between 0.010 and 0.029 jLg I`and PSA ) 0.030 jg I-'. Using the contingency table and chi-square test (or Fisher's exact test when necessary). we compared the differences in PSA concentration between breast cancer patients and normal women. between presurgical and post-surgical serum and between patients with PSA-positive and PSA-negative breast cancer. PSA-positive breast cancer was defined as a cancer with a PSA concentration ) 0.03 ng mg-' in the tumour cytosol. The selection of this cut-off point was based on criteria described elsewhere (Diamandis et al.. 1994) .
Pearson correlation coefficients were calculated for PSA concentrations between matched (i.e. from the same patient) presurgical and post-surgical sera. matched presurgical sera and tumour cytosols and matched post-surgical sera and tumour cytosols. The McNemar test was also used for comparison of PSA status, categorised into positive and negative groups with a cut-off level of 0.01 jIg ml-' for serum and 0.03 ng mg-' for tumour cytosols.
Results
The distribution of PSA concentrations in the serum of healthy women, the serum of women with breast cancer before or after surgery and in breast cancer cytosols is shown Serum PSM in wmen with breaS cancer M Gia et al 0 729 in Table I . The percentage of sera from presurgical breast cancer patients with PSA ) 0.03 jig I' is higher than the percentage of normal sera (110% vs 4%. P = 0.001). Similarly. the percentage of sera from post-surgical breast cancer patients with PSA > 0.03 jg I`is higher than the percentage of normal sera (9% vs 4%, P = 0.045). No difference was seen between presurgical and post-surgical sera (11% *s 900 P = 0.86). The percentage of breast tumour cytosols with PSA ) 0.03 ng mg-' (26-33%) is higher than the percentage of sera of either normal or breast cancer patients (P<0.001 for all comparisons and all age groups).
Similar statistical analysis was performed after all subjects were classified into two age groups. i.e. < 50 years and > 50 years. In the younger age group, the percentage of sera with PSA > 0.03 ig 1-' was still higher in the presurgical breast cancer group than in the healthy group (12% vs 4%. P= 0.003). However, no difference was seen between sera from healthy women and women with breast cancer. post surgery (3% *s 4%. P = 0.52). In the older age group the percentages of sera with PSA . 0.03 jig I' were similar in the healthy. presurgical or post-surgical groups (9% vs 11% vs 10%, P>0.8 in all cases) ( Table I) .
We have further compared the percentages of sera with PSA > 0.03 jg I-' between the group of breast cancer patients without any clinical information (n = 346) and healthy women. No statistically significant difference was found (P = 0.093 for ages < 50 years and P = 0.33 for ages ) 50 years).
The distribution of PSA concentrations in the serum of presurgical or post-surgical breast cancer patients whose tumours are either PSA positive or PSA negative is shown in Table II . The percentage of presurgical sera with PSA ) 0.03 jg I`was higher when the tumours were PSA negative. but the difference was not statistically significant (13% vs 7%. P = 0.053). Similarly. no difference was seen between the sera from post-surgical patients with PSApositive or PSA-negative tumours (P = 0.45, Table II) .
We have also correlated the PSA concentrations between presurgical and post-surgical sera (n = 118 pairs), between presurgical sera and tumour cytosols (n = 197) and between post-surgical sera and tumour cytosols (n = 119). The Pearson correlation coefficients were all below 0.02 and none was statistically significant (P . 0.78 in all three cases.
We have also analysed the possible associations of PSA levels between presurgical sera and tumour cytosols using categorical data and the McNemar test. PSA cut-off levels used were 0.01 jigl-for serum and 0.03 ngmg-1 for the tumours. There were 109 serum/tumour pairs negative for PSA, 33 pairs which were positive for PSA in the serum and negative in the tumour, 44 pairs which were negative in the serum and positive in the tumour and 11 pairs positive for PSA in both the serum and tumour. The P-value was 0.21, indicating no statistical significance.
From the statistical analysis we concluded that high levels of PSA in the tumour were not correlated with high PSA levels in the presurgical sera.
We have performed high-performance liquid chromatographic separation of the serum PSA subfractions (Figure 1 ). There are several possibilities which may have obscured an association between serum PSA and tumour cytosol PSA.
For example. patients who have PSA-positive cancer and PSA-negative serum may have some PSA in the serum that is not measurable by the method used. PSA levels in breast tumours are much lower than PSA levels in the prostate. Based on the ratio of PSA concentration in seminal plasma and serum (approximately 106) we may expect that serum PSA originating from the breast tumour is at a level below 0.01 lg -1 in most cases. In the prostate, PSA enters the circulation through physical diffusion (Oesterling et al., 1988; Oesterling. 1991) . Factors that affect the transport of PSA from the tissue to the blood may also be considered when one examines the relationship between PSA levels in the serum and tissue.
For those patients who had PSA-negative tumours and PSA-positive serum, there are at least two possible reasons to explain the phenomenon. First, it is conceivable that PSA is produced by foci of cells scattered throughout the tumour and that the examined tissue was negative owing to sampling bias. Second, we found that PSA can be produced by the normal breast tissue as well Diamandis, 1995c: Yu et al., 1995b) . Consequently, the serum PSA circulating in some women with or without cancer is probably released by the breast epithelial cells under stimulation by endogenous or exogenous steroid hormones. In the limited number of samples analysed, it appears that most of the PSA is present in its free form in the female serum but is present as ACT-PSA in the male serum (Figure 1 ). Free PSA also predominates in the breast tumour.
In summary, we found that there is no substantial difference between serum PSA levels from normal women and from women with breast cancer. No association was found between tumour PSA levels and serum PSA or between presurgical and post-surgical serum PSA levels. Based on these data we conclude that serum PSA levels are not useful for breast cancer patient diagnosis or monitoring. However, tumour levels of PSA appear to be valuable for breast cancer patient prognosis, since patients with PSApositive tumours have much longer disease-free and overall survival .
